NEU²: a competence consortium to deliver novel treatments for multiple sclerosis and other neurological diseases
The NEU² consortium integrates and synergistically refines existing MS expertise from academic centers, biotech and pharma companies. Our specific indication focus is in MS, but the NEU² members are representative of the major links in the drug discovery and development value chain. Each contributes one or more of their core clinical, scientific, or technical competencies, providing NEU² as a whole, with the necessary know-how to discover new therapies for MS and progress them to the clinic in order to benefit patients. The consortium is coordinated by Evotec International GmbH (Evotec).
This new drug discovery and development format enjoys the support of the Federal Ministry of Education and Research (BMBF). The NEU² parties attracted more than EUR 20 Mio of public funds as part of the “BioPharma Initiative” which helps to fund the execution of the consortium’s project portfolio until 2017.